The podocyte in diabetic kidney disease

TheScientificWorldJournal

Volumn 9, Issue , 2009, Pages 1127-1139

  Stitt Cavanagh, Erin ^a,b   MacLeod, Laura ^a   Kennedy, Chris R J ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Albuminuria; Diabetic kidney disease; Podocyte

Indexed keywords

ADIPONECTIN; ALAGEBRIUM; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN CONVERTING ENZYME 2; ANTIDIABETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; KIOM 79; LOSARTAN; LR 90; MICRORNA; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; PROSTAGLANDIN SYNTHASE; PROSTANOID; REACTIVE OXYGEN METABOLITE; RENIN; UNCLASSIFIED DRUG;

APOPTOSIS; CLINICAL TRIAL; DIABETES MELLITUS; EPITHELIUM CELL; GLOMERULOPATHY; GLOMERULUS BASEMENT MEMBRANE; GLYCATION; HUMAN; KIDNEY FAILURE; MICROALBUMINURIA; NONHUMAN; PODOCYTE; PODOCYTOPATHY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALS; DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; PODOCYTES; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM;

EID: 77649239864     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2009.133     Document Type: Review

References (128)

1. (2005) Incidence of end-stage renal disease among persons with diabetes--United States, 1990-2002. MMWR Morb. Mortal. Wkly. Rep. 54(43), 1097-1100.
2. Wolf, G. and Ritz, E. (2005) Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 67, 799-812.
3. Lewis, E.J. and Lewis, J.B. (2003) Treatment of diabetic nephropathy with angiotensin II receptor antagonist. Clin. Exp. Nephrol. 7, 1-8.
4. Remuzzi, G., Ruggenenti, P., Perna, A., Dimitrov, B.D., de Zeeuw, D., Hille, D.A., Shahinfar, S., Carides, G.W., and Brenner, B.M. (2004) Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J. Am. Soc. Nephrol. 15, 3117-3125.
5. Ruggenenti, P., Fassi, A., Ilieva, A.P., Bruno, S., Iliev, I.P., Brusegan, V., Rubis, N., Gherardi, G., Arnoldi, F., Ganeva, M., Ene-Iordache, B., Gaspari, F., Perna, A., Bossi, A., Trevisan, R., Dodesini, A.R., and Remuzzi, G. (2004) Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 351, 1941-1951.
6. Dronavalli, S., Duka, I., and Bakris, G.L. (2008) The pathogenesis of diabetic nephropathy. Nat. Clin. Pract. Endocrinol. Metab. 4, 444-452.
7. Kanwar, Y.S., Wada, J., Sun, L., Xie, P., Wallner, E.I., Chen, S., Chugh, S., and Danesh, F.R. (2008) Diabetic nephropathy: mechanisms of renal disease progression. Exp. Biol. Med. (Maywood) 233, 4-11.
8. Wolf, G. and Ziyadeh, F.N. (1999) Molecular mechanisms of diabetic renal hypertrophy. Kidney Int. 56, 393-405.
9. Wolf, G. and Ziyadeh, F.N. (2007) Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron. Physiol. 106, 26-31.
10. Ruggenenti, P. and Remuzzi, G. (2006) Time to abandon microalbuminuria? Kidney Int. 70, 1214-1222.
11. Anavekar, N.S., Gans, D.J., Berl, T., Rohde, R.D., Cooper, W., Bhaumik, A., Hunsicker, L.G., Rouleau, J.L., Lewis, J.B., Rosendorff, C., Porush, J.G., Drury, P.L., Esmatjes, E., Raz, I., Vanhille, P., Locatelli, F., Goldhaber, S., Lewis, E.J., and Pfeffer, M.A. (2004) Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int. Suppl. (92), S50-55.
12. Karalliedde, J. and Viberti, G. (2005) Hypertension and microalbuminuria: risk factors for cardiovascular disease in diabetes. Curr. Hypertens. Rep. 7, 1-2.
13. Karalliedde, J. and Viberti, G. (2004) Microalbuminuria and cardiovascular risk. Am. J. Hypertens. 17, 986-993.
14. Basi, S. and Lewis, J.B. (2006) Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am. J. Kidney Dis. 47, 927-946.
15. Remuzzi, G., Benigni, A., and Remuzzi, A. (2006) Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. 116, 288-296.
16. Remuzzi, A., Gagliardini, E., Sangalli, F., Bonomelli, M., Piccinelli, M., Benigni, A., and Remuzzi, G. (2006) ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int. 69, 1124-1130.
17. Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M.C., and Klein, R. (2009) Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. 361, 40-51.
18. Satchell, S.C. and Tooke, J.E. (2008) What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 51, 714-725.
19. Reddy, G.R., Kotlyarevska, K., Ransom, R.F., and Menon, R.K. (2008) The podocyte and diabetes mellitus: is the podocyte the key to the origins of diabetic nephropathy? Curr. Opin. Nephrol. Hypertens. 17, 32-36.
20. Wolf, G., Chen, S., and Ziyadeh, F.N. (2005) From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54, 1626-1634.
21. Jefferson, J.A., Shankland, S.J., and Pichler, R.H. (2008) Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int. 74, 22-36.
22. Russo, L.M., Sandoval, R.M., Campos, S.B., Molitoris, B.A., Comper, W.D., and Brown, D. (2009) Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J. Am. Soc. Nephrol. 20, 489-494.
23. Haraldsson, B., Nystrom, J., and Deen, W.M. (2008) Properties of the glomerular barrier and mechanisms of proteinuria. Physiol. Rev. 88, 451-487.
24. Deen, W.M. (2004) What determines glomerular capillary permeability? J. Clin. Invest. 114, 1412-1414.
25. Deen, W.M., Lazzara, M.J., and Myers, B.D. (2001) Structural determinants of glomerular permeability. Am. J. Physiol. Renal Physiol. 281, F579-596.
26. Steffes, M.W., Schmidt, D., McCrery, R., and Basgen, J.M. (2001) Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int. 59, 2104-2113.
27. Susztak, K., Raff, A.C., Schiffer, M., and Bottinger, E.P. (2006) Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55, 225-233.
28. Teiken, J.M., Audettey, J.L., Laturnus, D.I., Zheng, S., Epstein, P.N., and Carlson, E.C. (2008) Podocyte loss in aging OVE26 diabetic mice. Anat. Rec. (Hoboken) 291, 114-121.
29. Liu, Y. (2006) Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 69, 213-217.
30. Li, Y., Kang, Y.S., Dai, C., Kiss, L.P., Wen, X., and Liu, Y. (2008) Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am. J. Pathol. 172, 299-308.
31. Yamaguchi, Y., Iwano, M., Suzuki, D., Nakatani, K., Kimura, K., Harada, K., Kubo, A., Akai, Y., Toyoda, M., Kanauchi, M., Neilson, E.G., and Saito, Y. (2009) Epithelial-mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy. Am. J. Kidney Dis. 54(4), 653-664.
32. Strutz, F., Okada, H., Lo, C.W., Danoff, T., Carone, R.L., Tomaszewski, J.E., and Neilson, E.G. (1995) Identification and characterization of a fibroblast marker: FSP1. J. Cell Biol. 130, 393-405.
33. Iwano, M., Plieth, D., Danoff, T.M., Xue, C., Okada, H., and Neilson, E.G. (2002) Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 110, 341-350.
34. Okada, H., Danoff, T.M., Kalluri, R., and Neilson, E.G. (1997) Early role of Fsp1 in epithelial-mesenchymal transformation. Am. J. Physiol. 273, F563-574.
35. Chen, S. and Ziyadeh, F.N. (2008) Vascular endothelial growth factor and diabetic nephropathy. Curr. Diab. Rep. 8, 470-476.
36. Lewko, B. and Stepinski, J. (2009) Hyperglycemia and mechanical stress: targeting the renal podocyte. J. Cell Physiol. 221(2), 288-295.
37. Mertens, P.R., Raffetseder, U., and Rauen, T. (2008) Notch receptors: a new target in glomerular diseases. Nephrol. Dial. Transplant. 23, 2743-2745.
38. Ziyadeh, F.N. (2008) Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy. Diabetes Res. Clin. Pract. 82(Suppl 1), S38-41.
39. Philips, J.C., Weekers, L., and Scheen, A.J. (2001) [Clinical study of the month. The CALM study assessing the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist in the treatment of diabetic nephropathy]. Rev. Med. Liege 56, 126-128.
40. Mifsud, S.A., Allen, T.J., Bertram, J.F., Hulthen, U.L., Kelly, D.J., Cooper, M.E., Wilkinson-Berka, J.L., and Gilbert, R.E. (2001) Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with reninangiotensin blockade. Diabetologia 44, 878-882.
41. Langham, R.G., Kelly, D.J., Cox, A.J., Thomson, N.M., Holthofer, H., Zaoui, P., Pinel, N., Cordonnier, D.J. and Gilbert, R.E. (2002) Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 45, 1572-1576.
42. Durvasula, R.V., Petermann, A.T., Hiromura, K., Blonski, M., Pippin, J., Mundel, P., Pichler, R., Griffin, S., Couser, W.G., and Shankland, S.J. (2004) Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int. 65, 30-39.
43. Petermann, A.T., Pippin, J., Durvasula, R., Pichler, R., Hiromura, K., Monkawa, T., Couser, W.G., and Shankland, S.J. (2005) Mechanical stretch induces podocyte hypertrophy in vitro. Kidney Int. 67, 157-166.
44. Endlich, N., Kress, K.R., Reiser, J., Uttenweiler, D., Kriz, W., Mundel, P., and Endlich, K. (2001) Podocytes respond to mechanical stress in vitro. J. Am. Soc. Nephrol. 12, 413-422.
45. Martineau, L.C., McVeigh, L.I., Jasmin, B.J., and Kennedy, C.R. (2004) p38 MAP kinase mediates mechanically induced COX-2 and PG EP4 receptor expression in podocytes: implications for the actin cytoskeleton. Am. J. Physiol. Renal Physiol. 286, F693-701.
46. Durvasula, R.V. and Shankland, S.J. (2008) Activation of a local renin angiotensin system in podocytes by glucose. Am. J. Physiol. Renal Physiol. 294, F830-839.
47. Yoo, T.H., Li, J.J., Kim, J.J., Jung, D.S., Kwak, S.J., Ryu, D.R., Choi, H.Y., Kim, J.S., Kim, H.J., Han, S.H., Lee, J.E., Han, D.S., and Kang, S.W. (2007) Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int. 71, 1019-1027.
48. Xu, Z.G., Miao, L.N., Cui, Y.C., Jia, Y., Yuan, H., and Wu, M. (2009) Angiotensin II type 1 receptor expression is increased via 12-lipoxygenase in high glucose-stimulated glomerular cells and type 2 diabetic glomeruli. Nephrol. Dial. Transplant. 24, 1744-1752.
49. Parving, H.H., Persson, F., Lewis, J.B., Lewis, E.J., and Hollenberg, N.K. (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433-2446.
50. Dilauro, M. and Burns, K.D. (2009) Angiotensin-(1-7) and its effects in the kidney. TheScientificWorldJOURNAL 9, 522-535.
51. Reich, H.N., Oudit, G.Y., Penninger, J.M., Scholey, J.W., and Herzenberg, A.M. (2008) Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int. 74, 1610-1616.
52. Mizuiri, S., Hemmi, H., Arita, M., Ohashi, Y., Tanaka, Y., Miyagi, M., Sakai, K., Ishikawa, Y., Shibuya, K., Hase, H., and Aikawa, A. (2008) Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am. J. Kidney Dis. 51, 613-623.
53. Tikellis, C., Johnston, C.I., Forbes, J.M., Burns, W.C., Burrell, L.M., Risvanis, J., and Cooper, M.E. (2003) Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41, 392-397.
54. Leehey, D.J., Singh, A.K., Bast, J.P., Sethupathi, P., and Singh, R. (2008) Glomerular renin angiotensin system in streptozotocin diabetic and Zucker diabetic fatty rats. Transl. Res. 151, 208-216.
55. Ye, M., Wysocki, J., William, J., Soler, M.J., Cokic, I., and Batlle, D. (2006) Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J. Am. Soc. Nephrol. 17, 3067-3075.
56. Soler, M.J., Wysocki, J., Ye, M., Lloveras, J., Kanwar, Y., and Batlle, D. (2007) ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int. 72, 614-623.
57. Tikellis, C., Bialkowski, K., Pete, J., Sheehy, K., Su, Q., Johnston, C., Cooper, M.E., and Thomas, M.C. (2008) ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes 57, 1018-1025.
58. Wong, D.W., Oudit, G.Y., Reich, H., Kassiri, Z., Zhou, J., Liu, Q.C., Backx, P.H., Penninger, J.M., Herzenberg, A.M., and Scholey, J.W. (2007) Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am. J. Pathol. 171, 438-451.
59. Nguyen, G., Delarue, F., Burckle, C., Bouzhir, L., Giller, T., and Sraer, J.D. (2002) Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 109, 1417-1427.
60. Ichihara, A., Sakoda, M., Mito-Kurauchi, A., and Itoh, H. (2008) Activated prorenin as a therapeutic target for diabetic nephropathy. Diabetes Res. Clin. Pract. 82(Suppl 1), S63-66.
61. Nguyen, G. (2006) Renin/prorenin receptors. Kidney Int. 69, 1503-1506.
62. Li, J.M. and Shah, A.M. (2003) ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J. Am. Soc. Nephrol. 14, S221-226.
63. Gill, P.S. and Wilcox, C.S. (2006) NADPH oxidases in the kidney. Antioxid. Redox Signal. 8, 1597-1607.
64. Gorin, Y., Block, K., Hernandez, J., Bhandari, B., Wagner, B., Barnes, J.L., and Abboud, H.E. (2005) Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J. Biol. Chem. 280, 39616-39626.
65. Kim, N.H., Rincon-Choles, H., Bhandari, B., Choudhury, G.G., Abboud, H.E., and Gorin, Y. (2006) Redox dependence of glomerular epithelial cell hypertrophy in response to glucose. Am. J. Physiol. Renal Physiol. 290, F741-751.
66. Satoh, M., Fujimoto, S., Haruna, Y., Arakawa, S., Horike, H., Komai, N., Sasaki, T., Tsujioka, K., Makino, H., and Kashihara, N. (2005) NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am. J. Physiol. Renal Physiol. 288, F1144-1152.
67. Greiber, S., Munzel, T., Kastner, S., Muller, B., Schollmeyer, P., and Pavenstadt, H. (1998) NAD(P)H oxidase activity in cultured human podocytes: effects of adenosine triphosphate. Kidney Int. 53, 654-663.
68. Geiszt, M., Kopp, J.B., Varnai, P., and Leto, T.L. (2000) Identification of renox, an NAD(P)H oxidase in kidney. Proc. Natl. Acad. Sci. U. S. A. 97, 8010-8014.
69. Etoh, T., Inoguchi, T., Kakimoto, M., Sonoda, N., Kobayashi, K., Kuroda, J., Sumimoto, H., and Nawata, H. (2003) Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment. Diabetologia 46, 1428-1437.
70. Susztak, K., Raff, A.C., Schiffer, M., and Bottinger, E.P. (2006) Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55, 225-233.
71. Eid, A.A., Gorin, Y., Fagg, B.M., Maalouf, R., Barnes, J.L., Block, K., and Abboud, H.E. (2009) Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases. Diabetes 58, 1201-1211.
72. Zhao, H.J., Wang, S., Cheng, H., Zhang, M.Z., Takahashi, T., Fogo, A.B., Breyer, M.D., and Harris, R.C. (2006) Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J. Am. Soc. Nephrol. 17, 2664-2669.
73. Sato, W., Kosugi, T., Zhang, L., Roncal, C.A., Heinig, M., Campbell-Thompson, M., Yuzawa, Y., Atkinson, M.A., Grant, M.B., Croker, B.P., and Nakagawa, T. (2008) The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy. Lab. Invest. 88, 949-961.
74. Golbetz, H., Black, V., Shemesh, O., and Myers, B.D. (1989) Mechanism of the antiproteinuric effect of indomethacin in nephrotic humans. Am. J. Physiol. 256, F44-51.
75. Velosa, J.A. and Torres, V.E. (1986) Benefits and risks of nonsteroidal antiinflammatory drugs in steroid-resistant nephrotic syndrome. Am. J. Kidney Dis. 8, 345-350.
76. Velosa, J.A., Torres, V.E., Donadio, J.V., Jr., Wagoner, R.D., Holley, K.E., and Offord, K.P. (1985) Treatment of severe nephrotic syndrome with meclofenamate: an uncontrolled pilot study. Mayo Clin. Proc. 60, 586-592.
77. Vriesendorp, R., Brentjens, J.R., and Donker, A.J. (1985) Nonsteroidal antiinflammatory drugs in the nephrotic syndrome. Minerva Urol. Nefrol. 37, 211-219.
78. Vriesendorp, R., de Zeeuw, D., de Jong, P.E., Donker, A.J., Pratt, J.J., and van der Hem, G.K. (1986) Reduction of urinary protein and prostaglandin E2 excretion in the nephrotic syndrome by non-steroidal anti-inflammatory drugs. Clin. Nephrol. 25, 105-110.
79. Vriesendorp, R., Donker, A.J., de Zeeuw, D., de Jong, P.E., and van der Hem, G.K. (1985) Antiproteinuric effect of naproxen and indomethacin. A double-blind crossover study. Am. J. Nephrol. 5, 236-242.
80. Vriesendorp, R., Donker, A.J., de Zeeuw, D., de Jong, P.E., van der Hem, G.K., and Brentjens, J.R. (1986) Effects of nonsteroidal anti-inflammatory drugs on proteinuria. Am. J. Med. 81, 84-94.
81. Dunn, M.J. (1990) The roles of angiotensin II and prostaglandins in the regulation of the glomerular filtration of albumin. J. Hypertens. Suppl. 8, S47-51; discussion S51-42.
82. Noroian, G. and Clive, D. (2002) Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution. Drug Saf. 25, 165-172.
83. Perazella, M.A. (2002) COX-2 selective inhibitors: analysis of the renal effects. Expert Opin. Drug Saf. 1, 53-64.
84. Whelton, A. (1999) Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am. J. Med. 106, 13S-24S.
85. Breyer, M.D. and Breyer, R.M. (2001) G protein-coupled prostanoid receptors and the kidney. Annu. Rev. Physiol. 63, 579-605.
86. Epstein, M. (2002) Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunction. J. Hypertens. 20(Suppl 6), S17-23.
87. Blume, C., Heise, G., Muhlfeld, A., Bach, D., Schror, K., Gerhardz, C.D., Grabensee, B., and Heering, P. (1999) Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive heymann nephritis in the rat. Kidney Int. 56, 1770-1778.
88. Murray, M.D. and Brater, D.C. (1997) Effects of NSAIDs on the kidney. Prog. Drug Res. 49, 155-171.
89. Cheng, H.F. and Harris, R.C. (2002) Cyclooxygenase-2 expression in cultured cortical thick ascending limb of Henle increases in response to decreased extracellular ionic content by both transcriptional and post-transcriptional mechanisms. Role of p38-mediated pathways. J. Biol. Chem. 277, 45638-45643.
90. Hirose, S., Yamamoto, T., Feng, L., Yaoita, E., Kawasaki, K., Goto, S., Fujinaka, H., Wilson, C.B., Arakawa, M., and Kihara, I. (1998) Expression and localization of cyclooxygenase isoforms and cytosolic phospholipase A2 in anti-Thy-1 glomerulonephritis. J. Am. Soc. Nephrol. 9, 408-416.
91. Komers, R., Lindsley, J.N., Oyama, T.T., and Anderson, S. (2007) Cyclooxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats. Clin. Exp. Pharmacol. Physiol. 34, 36-41.
92. Komers, R., Lindsley, J.N., Oyama, T.T., Schutzer, W.E., Reed, J.F., Mader, S.L., and Anderson, S. (2001) Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J. Clin. Invest. 107, 889-898.
93. Wang, J.L., Cheng, H.F., Zhang, M.Z., McKanna, J.A., and Harris, R.C. (1998) Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Am. J. Physiol. 275, F613-622.
94. Ishibashi, R., Tanaka, I., Kotani, M., Muro, S., Goto, M., Sugawara, A., Mukoyama, M., Sugimoto, Y., Ichikawa, A., Narumiya, S., and Nakao, K. (1999) Roles of prostaglandin E receptors in mesangial cells under high-glucose conditions. Kidney Int. 56, 589-600.
95. Mene, P. and Dunn, M.J. (1986) Contractile effects of TxA2 and endoperoxide analogues on cultured rat glomerular mesangial cells. Am. J. Physiol. 251, F1029-1035.
96. Bek, M., Nusing, R., Kowark, P., Henger, A., Mundel, P., and Pavenstadt, H. (1999) Characterization of prostanoid receptors in podocytes. J. Am. Soc. Nephrol. 10, 2084-2093.
97. Makino, H., Tanaka, I., Mukoyama, M., Sugawara, A., Mori, K., Muro, S., Suganami, T., Yahata, K., Ishibashi, R., Ohuchida, S., Maruyama, T., Narumiya, S., and Nakao, K. (2002) Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist. J. Am. Soc. Nephrol. 13, 1757-1765.
98. Faour, W.H., Gomi, K., and Kennedy, C.R. (2008) PGE(2) induces COX-2 expression in podocytes via the EP(4) receptor through a PKA-independent mechanism. Cell. Signal. 20, 2156-2164.
99. Craven, P.A., Melhem, M.F., and DeRubertis, F.R. (1992) Thromboxane in the pathogenesis of glomerular injury in diabetes. Kidney Int. 42, 937-946.
100. Matsuo, Y., Takagawa, I., Koshida, H., Kawabata, T., Nakamura, M., Ida, T., Zhou, L., and Marumo, F. (1995) Antiproteinuric effect of a thromboxane receptor antagonist, S-1452, on rat diabetic nephropathy and murine lupus nephritis. Pharmacology 50, 1-8.
101. Sebekova, K., Eifert, T., Klassen, A., Heidland, A., and Amann, K. (2007) Renal effects of S18886 (Terutroban), a TP receptor antagonist, in an experimental model of type 2 diabetes. Diabetes 56, 968-974.
102. Xu, S., Jiang, B., Maitland, K.A., Bayat, H., Gu, J., Nadler, J.L., Corda, S., Lavielle, G., Verbeuren, T.J., Zuccollo, A., and Cohen, R.A. (2006) The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice. Diabetes 55, 110-119.
103. Issemann, I. and Green, S. (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650.
104. Berger, J. and Moller, D.E. (2002) The mechanisms of action of PPARs. Annu. Rev. Med. 53, 409-435.
105. Kumar, S., Boulton, A.J., Beck-Nielsen, H., Berthezene, F., Muggeo, M., Persson, B., Spinas, G.A., Donoghue, S., Lettis, S., and Stewart-Long, P. (1996) Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group. Diabetologia 39, 701-709.
106. Campbell, I.W. (2005) The clinical significance of PPAR gamma agonism. Curr. Mol. Med. 5, 349-363.
107. Lennon, R., Welsh, G.I., Singh, A., Satchell, S.C., Coward, R.J., Tavare, J.M., Mathieson, P.W., and Saleem, M.A. (2009) Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1. Diabetologia 52, 1944-1952.
108. Benigni, A., Zoja, C., Tomasoni, S., Campana, M., Corna, D., Zanchi, C., Gagliardini, E., Garofano, E., Rottoli, D., Ito, T., and Remuzzi, G. (2006) Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. J. Am. Soc. Nephrol. 17, 1624-1632.
109. Fukami, K., Yamagishi, S., Ueda, S., and Okuda, S. (2008) Role of AGEs in diabetic nephropathy. Curr. Pharm. Des. 14, 946-952.
110. Wendt, T.M., Tanji, N., Guo, J., Kislinger, T.R., Qu, W., Lu, Y., Bucciarelli, L.G., Rong, L.L., Moser, B., Markowitz, G.S., Stein, G., Bierhaus, A., Liliensiek, B., Arnold, B., Nawroth, P.P., Stern, D.M., D'Agati, V.D., and Schmidt, A.M. (2003) RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 162, 1123-1137.
111. Doublier, S., Salvidio, G., Lupia, E., Ruotsalainen, V., Verzola, D., Deferrari, G., and Camussi, G. (2003) Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 52, 1023-1030.
112. Figarola, J.L., Scott, S., Loera, S., Tessler, C., Chu, P., Weiss, L., Hardy, J., and Rahbar, S. (2003) LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin- diabetic rats. Diabetologia 46, 1140-1152.
113. Peppa, M., Brem, H., Cai, W., Zhang, J.G., Basgen, J., Li, Z., Vlassara, H., and Uribarri, J. (2006) Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711). Am. J. Nephrol. 26, 430-436.
114. Kim, Y.S., Kim, J., Kim, C.S., Sohn, E.J., Lee, Y.M., Jeong, I.H., Kim, H., Jang, D.S., and Kim, J.S. (2009) KIOM-79, an inhibitor of AGEs-protein cross-linking, prevents progression of nephropathy in Zucker diabetic fatty rats. Evid. Based Complement. Alternat. Med. [Epub ahead of print]
115. Ruster, C., Bondeva, T., Franke, S., Tanaka, N., Yamamoto, H., and Wolf, G. (2009) Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors. Am. J. Nephrol. 29, 538-550.
116. Sharma, K., Ramachandrarao, S., Qiu, G., Usui, H.K., Zhu, Y., Dunn, S.R., Ouedraogo, R., Hough, K., McCue, P., Chan, L., Falkner, B., and Goldstein, B.J. (2008) Adiponectin regulates albuminuria and podocyte function in mice. J. Clin. Invest. 118, 1645-1656.
117. Tsioufis, C., Dimitriadis, K., Chatzis, D., Vasiliadou, C., Tousoulis, D., Papademetriou, V., Toutouzas, P., Stefanadis, C., and Kallikazaros, I. (2005) Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am. J. Cardiol. 96, 946-951.
118. Tao, L., Gao, E., Jiao, X., Yuan, Y., Li, S., Christopher, T.A., Lopez, B.L., Koch, W., Chan, L., Goldstein, B.J., and Ma, X.L. (2007) Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 115, 1408-1416.
119. Ohashi, K., Iwatani, H., Kihara, S., Nakagawa, Y., Komura, N., Fujita, K., Maeda, N., Nishida, M., Katsube, F., Shimomura, I., Ito, T., and Funahashi, T. (2007) Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler. Thromb. Vasc. Biol. 27, 1910-1917.
120. Ahima, R.S. (2008) Linking adiponectin to proteinuria. J. Clin. Invest. 118, 1619-1622.
121. Cammisotto, P.G. and Bendayan, M. (2008) Adiponectin stimulates phosphorylation of AMP-activated protein kinase alpha in renal glomeruli. J. Mol. Histol. 39, 579-584.
122. Kato, M., Arce, L., and Natarajan, R. (2009) MicroRNAs and their role in progressive kidney diseases. Clin. J. Am. Soc. Nephrol. 4, 1255-1266.
123. Shi, S., Yu, L., Chiu, C., Sun, Y., Chen, J., Khitrov, G., Merkenschlager, M., Holzman, L.B., Zhang, W., Mundel, P., and Bottinger, E.P. (2008) Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J. Am. Soc. Nephrol. 19, 2159-2169.
124. Harvey, S.J., Jarad, G., Cunningham, J., Goldberg, S., Schermer, B., Harfe, B.D., McManus, M.T., Benzing, T., and Miner, J.H. (2008) Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J. Am. Soc. Nephrol. 19, 2150-2158.
125. Ho, J., Ng, K.H., Rosen, S., Dostal, A., Gregory, R.I., and Kreidberg, J.A. (2008) Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury. J. Am. Soc. Nephrol. 19, 2069-2065.
126. Sun, Y., Koo, S., White, N., Peralta, E., Esau, C., Dean, N.M., and Perera, R.J. (2004) Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res. 32, e188.
127. Tian, Z., Greene, A.S., Pietrusz, J.L., Matus, I.R., and Liang, M. (2008) MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res. 18, 404-411.
128. Kato, M., Zhang, J., Wang, M., Lanting, L., Yuan, H., Rossi, J.J., and Natarajan, R. (2007) MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc. Natl. Acad. Sci. U. S. A. 104, 3432-3437.